Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab +/- Imiquimod and Laser in Neoadjuvant BCC
NCT07251413Phase 2Recruiting
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cemiplimab in basal cell carcinoma (BCC) (2 arms), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoints: Incidence of Adverse Events at 3 weeks and Relapse-Free Survival at 3 years. Started Oct 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT07251413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251413.